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Background: Somatostatin receptor targeting radiopeptides are successfully being used to image, stage, and
monitor patients with neuroendocrine tumours. They are exclusively agonists that internalise upon binding to
the relevant receptor. According to recent reports, antagonists may be preferable to agonists. To date,
99mTc-labelled somatostatin receptor antagonists have attracted little attention. Here, we report on a new
somatostatin receptor subtype 2 (sst2) antagonist, SS-01 (p-Cl-Phe-cyclo(D-Cys-Tyr-D-Trp-Lys-Thr-Cys)D-Tyr-NH2), with
the aim of developing 99mTc-labelled ligands for SPECT/CT imaging. SS-01 was prepared using Fmoc solid-phase
synthesis and subsequently coupled to the chelators 1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid (DOTA),
6-carboxy-1,4,8,11-tetraazaundecane (N4), and 6-hydrazinonicotinic acid (HYNIC) to form the corresponding
peptide-chelator conjugates SS-03, SS-04, and SS-05, respectively. SS-04 and SS-05 were radiolabelled with
99mTc and SS-03 with 177Lu. Binding affinity and antagonistic properties were determined using autoradiography and
immunofluorescence microscopy. Biodistribution and small animal SPECT/CT studies were performed on mice bearing
HEK293-rsst2 xenografts.
Results: The conjugates showed low nanomolar sst2 affinity and antagonistic properties. 177Lu-DOTA-SS-01 (177Lu-SS-03)
and 99mTc-N4-SS-01 (99mTc-SS-04) demonstrated high cell binding and low internalisation, whereas 99mTc-HYNIC/
edda-SS-01 (99mTc-SS-05) showed practically no cellular uptake in vitro. The 99mTc-SS-04 demonstrated impressive
tumour uptake at early time points, with 47% injected activity per gram tumour (%IA/g) at 1 h post-injection. The
tumour uptake persisted after 4 h and was 32.5 %IA/g at 24 h. The uptake in all other organs decreased much more
rapidly leading to high tumour-to-normal organ ratios, which was reflected in high-contrast SPECT/CT images.
Conclusions: These data indicate a very promising 99mTc-labelled sst2-targeting antagonist. The results demonstrate
high sensitivity of the 99mTc-labelling strategy, which was shown to strongly influence the receptor affinity, contrary to
corresponding agonists. 99mTc-SS-04 exhibits excellent pharmacokinetics and imaging properties and appears to be a
suitable candidate for SPECT/CT clinical translation.
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Somatostatin receptors are important biomarkers for im-
aging and targeted radionuclide therapy of human can-
cers. They belong to the large family of G-protein
coupled receptors, which currently account for 30–40%
of marketed drugs [1] and are not only overexpressed in
neuroendocrine tumours in particular but also in
non-neuroendocrine tumours [2]. The receptors make
ideal targets for imaging, as they are easily accessible on
the plasma membrane of the tumour cell. Their action is
mediated through two mechanisms: G-protein activation
and β-arrestin function. Among its signalling roles, the
latter promotes receptor internalisation—an important
mechanism for radiolabelled agonist ligand uptake, accu-
mulation, and retention [3, 4].
In contrast, binding of neutral antagonists does not
lead to internalisation but potentially involves many
more binding sites than agonist-based approaches. This
may lead to the binding of a higher number of radio-
vectors and thus to a stronger signal originating from
the tumour. Ginj et al. have shown that in both in vitro
and in vivo animal models, somatostatin-based radioan-
tagonists may indeed be superior to radioagonists [5].
These findings have recently been duplicated with antag-
onists conjugated with DOTA and NODAGA and la-
belled with the positron-emitting radiometals 68Ga and
64Cu and other 3+ (radio)metals [6–8] and further sup-
ported by first-in-human imaging and therapy studies
[9–12]. Similarly, preclinical [13–16] and clinical [17]
studies of bombesin-based radioantagonists showed that
using antagonists may be advantageous over agonists for
targeted imaging and therapy of GRP receptor-express
ing tumours.
Despite the fact that the first somatostatin-based
radioantagonists have been studied in humans and
proven to be superior to registered radioagonists, little is
known about the influence of bioconjugation, labelling
strategies, and other modifications on the in vitro and
in vivo pharmacology of radiolabelled antagonists.
Wadas et al. compared a potent agonist, TATE ([Tyr3,-
Thr8]octreotide) labelled with 64Cu using CB-TE2A, a
cross-bridged cyclam-14 derivative, with the antagonist
(sst2-ANT, p-NO2-Phe-cyclo(D-Cys-Tyr-D-Trp-Lys-Thr-
Cys)D-Tyr-NH2), labelled using the same strategy [18].
They showed that the radioantagonist had lower tumour
uptake despite the much higher receptor numbers found
in the AR42J tumour model. AR42J cells endogenously
express sst2 receptors. The authors also reported a much
lower receptor affinity for the antagonist, which might
be the reason for the difference rather than the origin of
the receptor (natural or transfected), as proposed by the
authors.
Even more intriguing is a study by Dude et al. [19],
who compared the antagonist 68Ga-NODAGA-JR11 withthe two agonists 68Ga-DOTATOC and 68Ga-DOTATA
TE. Surprisingly, the authors found that 68Ga-NODA-
GA-JR11 has the lowest tumour uptake in their human
ZR-75-1 breast tumour model. In addition, the number
of receptors using 68Ga-DOTATOC was more than two-
fold higher than 68Ga-DOTATATE and significantly
higher than the antagonist.
More clinically relevant, however, is the fact that the
phenomenon of higher tumour uptake of antagonists
was also observed in human tumours. Reubi et al. per-
formed quantitative autoradiography in neuroendocrine
and non-neuroendocrine tumour specimens using the
125I-DOTA-JR11 antagonist and 125I-Tyr3octreotide
agonist and found up to tenfold higher uptake of the an-
tagonist radioligand compared to the agonist. The au-
thors concluded that all renal cell cancers, most breast
cancers, non-Hodgkin lymphomas, and medullary thy-
roid cancers appear to be novel targets for in vivo target-
ing with sst2 radioantagonists [20].
These different observations emphasise the need to
study the influence of overall structure on pharmacology
in vitro and in vivo in different cell and tumour models.
In particular, modifications allowing 99mTc-labelling have
only been studied in one case [21], although 99mTc-la-
belled radiopharmaceuticals are still the mainstay of nu-
clear medicine. We report here the synthesis of a new
somatostatin-based antagonist, 4-Cl-Phe-cyclo(D-Cys-
Tyr-D-Trp-Lys-Thr-Cys)D-Tyr-NH2 (SS-01), which was
designed for labelling with 99mTc using two different
strategies, namely N4: 6-carboxy-1,4,8,11-tetraazaunde-
cane (SS-04) and HYNIC: 6-hydrazinopyridine-3-carbox-
ylic acid (SS-05), as metal-binding domains. The choice
of the chemical structure of the antagonist was based on
our previous experiences. We and others observed that
the chirality change of amino acids 1 and 2 (aa1, aa2)
and C-terminal amidation compared to octreotide type
octapeptides transforms an agonist into an antagonist
[22, 23]. In addition, we chose the most easily accessible
amino acids leading to antagonistic peptides. To serve as
a control, we also modified the peptide with DOTA for
labelling with 177Lu (177Lu-SS-03).
Methods
The supplier information for reagents, radiolabelling pro-
tocols, and log D determination, as well as details about
instrumentation, are provided in the Additional file 1.
Synthesis of chelator-peptide conjugates, radiochemistry
The peptides were assembled on the Rink-Amide methyl-
benzylhydryl (MBHA) resin employing standard Fmoc
strategy. The coupling reactions were performed on a
semiautomatic peptide synthesiser (RinkCombichem,
Bubendorf, Switzerland) with a threefold excess of Fmoc-
amino acids, using DIC/HOBt as activating agents in
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cluding labelling protocols and corresponding high-
performance liquid chromatography (HPLC) data).
Binding affinity measurements
Cell membrane pellets were prepared from human
sst1-expressing Chinese hamster ovary cells (kindly pro-
vided by Drs. T. Reisine and G. Singh, University of
Pennsylvania, Philadelphia, Pa.); sst2-, sst3-, and sst4-ex-
pressing CCL39 cells (kindly provided by Dr. D. Hoyer,
Novartis Pharma, Basel, Switzerland); and sst
5
-expressing
human embryonic kidney 293 (HEK293) cells (kindly
provided by Prof. Stefan Schulz, University of Jena,
Germany) and stored at − 80 °C. Quantitative receptor
autoradiography was performed on 20-μm-thick mem-
brane pellet sections and quantitated as previously
described [22, 24].
Immunofluorescence microscopy
An immunofluorescence microscopy-based internalisa-
tion assay was performed on HEK293-rsst2 cells, as pre-
viously described [22]. Briefly, the cells were treated with
different antagonist chelator-peptide conjugates and/or
[Tyr3]octreotide (TOC) (the sst2 agonist) at 37 °C for
30 min. After fixation and permeabilisation, cells were
stained with the sst2-specific primary antibody R2-88
(provided by Dr. Agnes Schonbrunn, McGovern Medical
School, University of Texas Health Science Center,
Houston, Texas, USA) as described previously [25, 26].
The cells were imaged using a Leica DM RB immuno-
fluorescence microscope, and the images were acquired
using an Olympus DP10 camera.
Receptor-binding, internalisation, and dissociation
kinetics
The receptor binding, internalisation, and dissociation
rates of 177Lu-SS-03, 99mTc-SS-04, and 99mTc-SS-05 were
studied in HEK293-rsst2 cells seeded in six-well plates,
as described previously [6]. Briefly, the radiopeptide
(0.25 pmol/well) was added and the cells were incubated
at 37 °C. At different time points (0.5, 1, 2, and 4 h), the
cellular uptake was stopped by washing twice with
ice-cold PBS. The membrane-bound and internalised
fractions were collected with ice-cold glycine buffer, pH
2.8 and 1 M NaOH, respectively.
For the dissociation experiments, the plates were
placed on ice for 30 min. The radiopeptide (0.25 pmol/
well) was added to the cells and allowed to bind for 2 h
at 4 °C. The cells were then quickly washed with
ice-cold PBS, and fresh pre-warmed (37 °C) medium was
added. The cells were incubated at 37 °C for 10, 20, 30,
60, 120, and 240 min. The medium was collected for
quantification, and the cells were treated as described
previously [6].The activity in each fraction was measured in a
γ-counter (Cobra II). Nonspecific uptake was deter-
mined in the presence of 250 pmol/well [Tyr3]octreo-
tide. The results were expressed as a percentage of the
applied radioactivity.
Biodistribution studies in HEK293-rsst2-bearing mice
All animal experiments were conducted in compliance
with Swiss animal protection laws and associated regula-
tions. The protocol was approved by the Cantonal Veter-
inary Ethics Committee of the University of Basel
(approval #789). Female athymic nude mice (4–6 weeks
old) were injected subcutaneously (s.c.) in the right
shoulder with 107 HEK293-rsst2 cells in 100 μL sterile
PBS. The tumours were allowed to grow for 14–18 days
(tumour weight 100–200 mg).
The mice were injected into the tail vein with 100 μL/
10 pmol/0.37 MBq of 177Lu-SS-03 or 99mTc-SS-04 and
were euthanised at 1, 4, and 24 h post-injection (p.i.).
Organs of interest and blood were collected, rinsed of
excess blood, blotted dry, weighed, and counted in a
γ-counter. To determine nonspecific uptake, three ani-
mals were pre-injected with 20 nmol of the relevant un-
labelled peptide in 0.9% NaCl solution (0.1 mL); after
5 min, the radiopeptide was injected and the percentage
of injected activity per gram (%IA/g) was calculated for
each tissue. The total counts injected per animal were
determined by extrapolation from counts of an aliquot
taken from the injected solution as a standard.
SPECT/CT imaging study
Mice bearing HEK-rsst2 tumours were euthanised 4 h
after intravenous injection of 15 MBq (150 pmoles) of
99mTc-SS-04 and imaged supine, head first, using a
SPECT/CT system dedicated to imaging small animals
(NanoSPECT/CT™ Bioscan Inc.). Topogram and helical
CT scan of the whole mouse was first acquired using the
following parameters: X-ray tube current 177 μA, X-ray
tube voltage 45 kVp, 90 s and 180 frames per rotation,
pitch 1. The helical SPECT scan was then acquired from
head to toe using multi-purpose pinhole collimators
(APT1). The energy window width was 20% centred
symmetrically over the energy peak of 99mTc at 140 keV.
Twenty-four projections (200 s per projection) were
used, allowing the acquisition of at least 50 kilocounts/
projection.
SPECT images were reconstructed iteratively and filtered
using the software package (HiSPECT v1.4.1876, SciVis
GmbH, Goettingen, Germany) and the manufacturer’s algo-
rithm (3 subsets, 9 iterations, 35% post-filtering, 128 × 128
matrix, zoom 1, 30 × 20 mm transaxial field of view, result-
ing in a pixel size of 0.3 mm). CT images were recon-
structed using CTReco version r1.146, with a standard
filtered back projection algorithm (Exact Cone Beam) and
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a pixel size of 0.2 mm. Co-registered images were visualised
in the three orthogonal planes and as maximal intensity
projection with InVivoScope v1.43 (Bioscan Inc.).Data analysis
Statistical analysis was performed using an unpaired
two-tailed t test with Prism software (Prism 5.01,
September 2007, GraphPad Software Inc.). Differences at
the 95% confidence level (P < 0.05) were considered
significant.Results
Synthesis, radiolabelling, and distribution coefficients (log
D)
All conjugates (Fig. 1) were synthesised with the max-
imum yield of 30–40% and purity ≥ 97%. The conjugates
were characterised by analytical reversed phase HPLC
and ESI-MS (Table 1, Additional file 1).
SS-03 was labelled with 177Lu with labelling yields of >
97% at a maximum specific activity of 50 GBq/μmol. The
conjugates SS-04 and SS-05 were labelled with 99mTc at
room temperature (30 min) and elevated temperature
(95 °C, 10 min), respectively. Tin(II)chloride was used as
the reducing agent and citrate as an intermediate support-
ing Tc(V) ligand for the labelling of SS-04. For SS-05,
99mTc labelling was performed using edda (ethylenedi-
amine, N,N′-diacetic acid) as coligand. The radiolabellingFig. 1 Structures of the somatostatin receptor subtype 2 antagonist conjugyields of both 99mTc-SS-04 and 99mTc-SS-05 were > 97% at
a specific activity of approximately 100 GBq/μmol.
The distribution coefficients (log D) were determined
using the shake-flask method (see Additional file 1). All
radiopeptides showed high hydrophilicity (99mTc-SS-04,
log D = − 2.49 ± 0.34, 177Lu-SS-03, log D = − 2.35 ± 0.22
and 99mTc-SS-05, log D = − 2.03 ± 0.27).Binding affinity and immunofluorescence microscopy
Table 2 summarises the IC50 values of SS-03 and SS-04
for the five somatostatin receptor subtypes (sst1-sst5).
Both SS-03 and SS-04 show high selectivity and affinity
to sst2. The affinity of SS-03 for the sst2 subtype is
threefold higher than SS-04. In comparison with natural
somatostatin-28 (SS-28) and the potent sst2 antagonist
DOTA-sst2-ANT (DOTA-pNO2Phe-cyclo[D-Cys-Tyr-D-
Trp-Lys-Thr-Cys]-D-Tyr-NH2), both SS-03 and SS-04
retained high affinity to sst2.
Immunofluorescence-based internalisation was per-
formed using HEK-sst2 cells to demonstrate the antag-
onistic property of the conjugates. Figure 2 illustrates
that 10 nM of the agonist [Tyr3]octreotide (TOC) trig-
gers massive receptor internalisation, whereas SS-03 or
SS-04 at the much higher concentration of 1000 nM
does not stimulate receptor internalisation. However, at
a concentration of 1 μM together with 10 nM of TOC,
the conjugates were able to prevent the agonist-induced
receptor internalisation.ated to different chelators
Table 1 Analytical data of the purified chelator-peptide conjugates
Compound Sequence Molecular weight (g/mol) m/z (calc.) MS (ESI):(m/z) Purity (%)
SS-03 DOTA-(4-Cl)-Phe-Cyclo(D-Cys-Tyr-D-Trp-Lys-Thr-Cys)-D-Tyr-NH2 1531.15 1529.59 767.2 [M+2H]
++ 99.5
1531.8 [M+H]+
SS-04 N4-(4-Cl)-Phe-Cyclo(D-Cys-Tyr-D-Trp-Lys-Thr-Cys)-D-Tyr-NH2 1331.01 1329.56 667.7 [M+2H]
++ 98
1332 [M+H]+
SS-05 HYNIC-(4-Cl)-Phe-Cyclo(D-Cys-Tyr-D-Trp-Lys-Thr-Cys)-D-Tyr-NH2 1279.88 1278.45 642 [M+2H]
++ 97
1280.8 [M+H]+
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Figure 3 shows the cellular uptake profiles of the radioli-
gands as measured with HEK-rsst2 cells. 177Lu-SS-03
and 99mTc-SS-04 showed high uptake and blocking stud-
ies demonstrated that the uptake was receptor-mediated.
Within 2 h of incubation, the specifically bound fraction
levelled off at 48%, demonstrating rapid binding of
177Lu-SS-03 and 99mTc-SS-04 to the receptors. The
internalised fraction was about 8–10% and increased
very slowly. Surprisingly, 99mTc-SS-05 showed very low
cellular uptake of < 1% even after 4 h of incubation.
The dissociation kinetics of 177Lu-SS-03 and 99mTc-
SS-04 were studied by a temperature shift experiment
and showed a plateau at 2 h, indicating that a steady
state had been achieved (Fig. 4). Both conjugates bind
strongly to the receptor, displaying only 30 and 48% of
dissociation, respectively, after 4 h at 37 °C.
Biodistribution studies and SPECT imaging
Table 3 summarises the biodistribution of 177Lu-SS-03
and 99mTc-SS-04 evaluated at 1, 4, and 24 h after injection
in HEK-rsst2 xenografts. At 1 h, 99mTc-SS-04 showed high
uptake in the liver (7.18 ± 0.40 %IA/g) and kidneys (49.82
± 4.31 %IA/g) and higher blood pool activity (1.85 ± 0.41
%IA/g) than 177Lu-SS-03 (liver 3.00 ± 0.66 %IA/g, kidneys
15.15 ± 1.86 %IA/g, and blood 0.57 ± 0.04 %IA/g).
99mTc-SS-04 exhibits twofold higher tumour uptake com-
pared to 177Lu-SS-03. Uptake in other sst2 receptor-
positive organs such as the stomach and pancreas is lower
for 99mTc-SS-04 (11.1 ± 2.9 and 15.6 ± 0.8 %IA/g, respect-
ively) than 177Lu-SS-03 (48.7 ± 13.1 and 72.6 ± 13.8 %IA/g,
respectively). At 4 h, the tumour uptake of 177Lu-SS-03 in-
creased to 31.68 ± 4.00 %IA/g, whereas the tumour uptakeTable 2 Binding affinities (IC50, nM) of chelator-peptide conjugates
Compound IC50 (nM)*
sst1 sst2 sst3 sst4 sst5
SS-03 > 1000 1.7 ± 0.06 > 1000 404 ± 92 564 ± 174
SS-04 > 1000 5.3 ± 0.17 720 ± 74 171 ± 35 228 ± 73
DOTA-sst2-ANT [22] > 1000 1.5 ± 0.4 > 1000 287 ± 27 > 1000
SS-28 5.2 ± 0.3 2.7 ± 0.38 7.7 ± 0.9 5.6 ± 0.4 4.0 ± 0.3
*Values are IC50 in nM (mean ± SEM; n ≥ 3)of 99mTc-SS-04 remained constant. Tumour uptake of
177Lu-SS-03 and 99mTc-SS-04 was significantly reduced by
pre-injection of 20 nmol of unlabelled peptide. At 24 h,
both conjugates showed clearance from the blood pool (<
0.1 %IA/g) and significant wash-out from the liver
(177Lu-SS-03: 0.47 ± 0.07 %IA/g and 99mTc-SS-04: 1.87 ±
0.33 %IA/g) and kidneys (177Lu-SS-03: 7.3 ± 1.6 %IA/g and
99mTc-SS-04: 6.3 ± 1.8 %IA/g). 99mTc-SS-04 showed higher
tumour uptake at all time points including 24 h p.i. (32.5
± 0.78 %IA/g) compared to 177Lu-SS-03 (26.32 ± 4.42
%IA/g). The tumour-to-normal tissue ratios of 177Lu-
SS-03 and 99mTc-SS-04 at each time point are illustrated
in Table 4. At 1 h, 177Lu-SS-03 shows higher tumour-
to-normal tissue ratios compared to 99mTc-SS-04. At 4 h,
both radiopeptides showed similar ratios except 177Lu-SS-
03 had a twofold higher tumour-to-liver ratio. However, at
24 h, 99mTc-SS-04 exhibited excellent biodistribution with
a 4.5-fold higher tumour-to-blood ratio, approximately
threefold higher tumour-to-kidney ratio, and approxi-
mately twofold higher tumour-to-liver ratio compared to
177Lu-SS-03. All relevant tumour-to-normal organ ratios
increased with time and were > 4 at 24 h.
The SPECT/CT images (Fig. 5) were acquired at 4 h
after intravenous injection of 99mTc-SS-04. The highest
uptake was visible in the tumour and the kidneys. To a
lesser extent, uptake was also visible in the abdomen due
to tracer accumulation in the sst2-expressing organs.Discussion
Radiolabelled peptides targeting G-protein-coupled recep-
tors have been an important focus in the radiopharmaceu-
tical and nuclear oncology fields over the last 20 years
[27–29]. The clinically employed somatostatin receptor-
targeting peptides are agonists, which exhibit nanomolar
binding affinities and fast receptor-mediated internalisa-
tion in vitro and in vivo via endocytosis. More recently,
sst2 antagonists were studied in animal models [6–8, 18]
and in humans [9–12]. Surprisingly, the antagonists
showed high and long-lasting tumour uptake in most
cases. However, antagonist superiority cannot be general-
ised, as shown by Wadas et al. [18] and Dude et al. [19].
To date, many peptides labelled with gamma-, posi-
tron-, and beta-emitters (111In, 64Cu, 68Ga, and 177Lu)
Fig. 2 Immunofluorescence microscopy-based internalisation assay on HEK-sst2 cells. Immunofluorescence microscopy-based internalisation assay
with HEK-sst2 cells showing the sst2 internalisation induced by [Tyr3]octreotide (TOC) is efficiently antagonised by SS-03 and SS-04. Control experiment
showing membrane bound sst2-receptor in the absence of peptide. The agonist, TOC, triggered massive sst2-receptor internalisation at a concentration of
10 nM. The antagonists SS-03 and SS-04 failed to induce sst2 internalisation even at a concentration of 1 μM. Further, both SS-03 and SS-04 at a concentration
of 1 μM efficiently blocked the agonist (TOC, 10 nM)-mediated sst2-receptor internalisation
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onist has been reported to date [21].
We selected two of the more popular and successful
chelators for 99mTc: HYNIC with the co-ligand edda (ethy-
lenediamine-N,N′-diacetic acid) and the bifunctional tetra-
amine N4. The HYNIC core has been widely used for the
labelling of octreotide-based somatostatin receptor-target
ing peptides, and the [HYNIC, Tyr3]octreotide/edda kit
(HYNIC-TOC) is registered in some European countries.
The [O=Tc=O]+ core is formed with linear and macrocyclic
tetraamines such as 1,4,8,11-tetraazaundecane and cyclam-
14. This core exhibits high kinetic stability, can be labelled
at room temperature, is highly hydrophilic, and with differ-
ent functions in 6-position, such as carboxylic acid can be
easily coupled to the N-termini of biomolecules [30]. We
have conjugated these two chelators to a new antagonist,
p-Cl-Phe-cyclo(D-Cys-Tyr-D-Trp-Lys-Thr-Cys)D-TyrNH2.
As mentioned earlier, we chose the most easily accessible
amino acids leading to antagonistic peptides. Our new an-
tagonist is based on a modification of the first radiolabelled
sst2 antagonists (DOTA-BASS) [5, 9, 31], where the p-
NO2-Phe has been replaced by p-Cl-Phe. We also conju-
gated DOTA to this antagonist and labelled the conjugate
with 177Lu for comparative in vitro and in vivo studies.
The antagonistic properties of SS-03 and SS-04 were
investigated using immunofluorescence microscopy; the
two compounds inhibit receptor internalisation triggered
by the potent agonist [Tyr3]octreotide but do not trigger
internalisation on their own. Somewhat surprisingly, butas previously reported [6, 14, 17], we observed low but
significant cell internalisation of 177Lu-SS-03 and
99mTc-SS-04 (around 10% of the added radiopeptide ac-
tivity per one million cells at 4 h). This uptake can be
blocked by excess unlabelled peptide. The internalisation
rate is significantly lower than that of somatostatin-
based radiolabelled agonists [14, 22, 32]. The reason for
the difference between the two assays is unclear.
A very important outcome of this work is that
[99mTc-HYNIC/edda]-SS-01 shows practically no cell
binding or internalisation in our HEK-rsst2 cell assay.
This is contrary to HYNIC conjugated to somatostatin-
based agonistic octapeptides such as [Tyr3]octreotide
(TOC) and [Tyr3,Thr8]octreotide (TATE). These conju-
gates showed impressive preclinical [3] and clinical
pharmacokinetics [33–35]. The influence of chelator and
even radiometal on the pharmacologic properties was
also reported for DOTA- and NODAGA-conjugated sst2
antagonists [6, 7].
In contrast, the N4-conjugated and 99mTc-labelled
radiopeptide showed superior properties, with very high
cell uptake in vitro and about the highest tumour uptake
at 1 and 4 h of any somatostatin-based radiopeptide
studied to date in this xenograft model [6, 7]. The higher
tumour uptake of 99mTc-SS-04, compared with 177Lu-
SS-03, may be attributed to the somewhat slower blood
clearance of 99mTc-SS-04, even though at 4 h p.i, the
blood values are at the same level for both radiopeptides.
In addition, it shows very good tumour retention, no
Fig. 3 In vitro cellular uptake profile of the radioligands on HEK293-rsst2 cells. Cellular uptake profile of 177Lu-SS-03 (circle), 99mTc-SS-04 (square),
and 99mTc-SS-05 (triangle) as measured with HEK293-rsst2 cells. a The amount of specifically internalised and b radiopeptides specifically bound
to the membrane. Values and standard deviations are the result of two independent experiments with triplicates in each experiment
Fig. 4 Dissociation kinetics of the cell surface bound radioligands on
HEK293-rsst2 cells. Dissociation kinetics of membrane bound 177Lu-SS-03
(circle) and 99mTc-SS-04 (square) as measured with HEK293-rsst2 cells. The
profile illustrates the varying degree of dissociation kinetics exhibited by
177Lu-SS-03 (koff = 0.037 min-1 and t1/2 = 18.66 min) and 99mTc-SS-04
(koff = 0.040 min-1 and t1/2 = 17.24 min). Values and standard deviations
are the result of two independent experiments with triplicates in each
experiment. The rate constants were determined by fitting to a
pseudofirst order reaction using GraphPad Prism
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between 1 and 24 h p.i. The target-to-relevant organ ra-
tios are > 5 at 24 h, reflected in excellent SPECT/CT im-
ages. For both radiotracers, the kidney uptake is
somewhat high but the tumour-to-kidney ratios are still
within a reasonable range when compared to potent
radioagonists. We are currently studying somewhat dif-
ferent peptide motifs coupled to tetraamine chelators for
99mTc-labelling to improve the overall pharmacokinetics.
The hypothesised improvement is based on the proper-
ties of 177Lu-SS-03, which exhibits pharmacokinetics
somewhat inferior to the previously published 111In-DOTA
and 177Lu-DOTA conjugated antagonists [31]. As previ-
ously mentioned, Radford et al. studied a somewhat differ-
ent sst2 antagonist peptide labelled using the 99mTc
tricarbonyl strategy and an NSN-type chelator [21]. The
Re-complexed congener showed reasonably good receptor
affinity indicating that this strategy, other than the HYNIC
strategy, retains binding affinity [21]. The problem with the
radioligand is its high abdominal uptake and low
tumour-to-normal organ ratios, which is below 1 for some
relevant tissues. As the authors pointed out, this is due to
Table 4 Tumour-to-normal tissue ratios of 177Lu-SS-03 and
99mTc-SS-04 after 1, 4, and 24 h of administration in nude mice
bearing HEK293-rsst2 tumour xenografts
177Lu-SS-03 99mTc-SS-04
1 h 4 h 24 h 1 h 4 h 24 h
Tumour/blood 41.3 150.5 360.9 25.5 218.1 981.3
Tumour/liver 7.9 18.1 55.8 6.6 9.2 17.4
Tumour/kidney 1.56 1.86 3.58 0.95 1.85 5.16
Tumour/muscles 109.5 259.3 372.1 73.6 382.1 616.7
Tumour/bone 5.7 11.5 21.1 14.9 51.3 74.1
Fig. 5 SPECT/CT imaging of 99mTc-SS-04 on HEK-rsst2-xenograft-bearing
mouse. Maximum intensity projection (MIP) of the nanoSPECT/CT image
acquired 4 h after injection of 15 MBq (150 pmol peptide) 99mTc-SS-04 in
a HEK-rsst2-xenograft-bearing mouse. The colour bar corresponds
to 0–90%IA/g
Table 3 Biodistribution results of 177Lu-SS-03 and 99mTc-SS-04 in
nude mice bearing HEK293-rsst2 tumour xenografts. Data
expressed as %IA/g (percentage of injected activity per gram)
and presented as mean ± SD (n = 3–5)
Organs 1 h 4 h 4 h blocking* 24 h
177Lu-SS-03
Blood 0.57 ± 0.04 0.21 ± 0.04 0.07 ± 0.02 0.07 ± 0.04
Heart 0.69 ± 0.12 0.38 ± 0.07 0.11 ± 0.01 0.11 ± 0.04
Liver 3.00 ± 0.66 1.75 ± 0.22 1.04 ± 0.09 0.47 ± 0.07
Spleen 1.51 ± 0.19 1.42 ± 0.77 0.28 ± 0.04 0.33 ± 0.06
Lung 13.24 ± 4.49 6.71 ± 1.37 0.59 ± 0.11 0.74 ± 0.22
Kidney 15.15 ± 1.86 17.04 ± 1.81 20.24 ± 4.30 7.35 ± 1.66
Stomach 48.74 ± 13.11 30.21 ± 4.25 0.37 ± 0.06 6.02 ± 1.40
Intestine 3.13 ± 1.16 2.28 ± 0.31 0.24 ± 0.03 0.27 ± 0.06
Adrenal 3.70 ± 0.63 2.90 ± 0.46 0.06 ± 0.03 1.16 ± 0.46
Pancreas 72.61 ± 13.77 54.49 ± 7.28 0.24 ± 0.07 3.03 ± 0.62
Muscle 0.22 ± 0.06 0.12 ± 0.02 0.06 ± 0.00 0.07 ± 0.02
Bone 4.11 ± 0.53 2.77 ± 1.06 0.12 ± 0.03 1.25 ± 0.16
Tumour 23.64 ± 1.28 31.68 ± 4.00 11.15 ± 1.93 26.32 ± 4.42
99mTc-SS-04
Blood 1.85 ± 0.41 0.22 ± 0.03 0.22 ± 0.01 0.03 ± 0.01
Heart 1.42 ± 0.30 0.25 ± 0.06 0.23 ± 0.02 0.09 ± 0.01
Liver 7.18 ± 0.40 5.13 ± 0.51 4.07 ± 0.65 1.87 ± 0.33
Spleen 2.09 ± 0.34 0.85 ± 0.08 0.63 ± 0.02 0.41 ± 0.11
Lung 15.93 ± 2.69 2.03 ± 0.14 2.00 ± 0.37 0.54 ± 0.10
Kidney 49.82 ± 4.31 25.56 ± 1.01 18.48 ± 3.66 6.31 ± 1.82
Stomach 11.13 ± 2.98 1.99 ± 0.39 0.56 ± 0.03 0.62 ± 0.14
Intestine 2.12 ± 0.57 0.57 ± 0.06 0.42 ± 0.03 0.16 ± 0.02
Adrenal 3.17 ± 0.69 0.99 ± 0.20 0.37 ± 0.10 0.50 ± 0.13
Pancreas 15.58 ± 0.82 1.16 ± 0.86 0.33 ± 0.06 0.31 ± 0.11
Muscle 0.64 ± 0.13 0.12 ± 0.02 0.12 ± 0.02 0.05 ± 0.03
Bone 3.15 ± 0.72 0.92 ± 0.15 0.40 ± 0.01 0.44 ± 0.23
Tumour 47.14 ± 7.23 47.24 ± 7.96 14.17 ± 1.69 32.51 ± 0.78
*Pre-injection with 20 nmol of unlabelled peptide (SS-03 or SS-04)
Abiraj et al. EJNMMI Research  (2018) 8:75 Page 8 of 10the high lipophilic character of the radioligand. The new
99mTc-based sst2 antagonist 99mTc-SS-04 is hydrophilic, as
indicated by its log D value. Consequently, it has limited ac-
cumulation in the abdomen and rather high renal excre-
tion. The biodistribution profile of 99mTc-SS-04, together
Abiraj et al. EJNMMI Research  (2018) 8:75 Page 9 of 10with its very high tumour uptake, favours this tracer for
clinical translation.
Conclusions
Sst2 antagonists were labelled with 99mTc using two
common chelators. Surprisingly, the widely used 99mTc
ligand HYNIC along with the co-ligand edda resulted in
almost complete loss of sst2 binding affinity, whereas
99mTc-SS-04 demonstrated impressive tumour uptake
and high tumour-to-normal organ ratios. Therefore,
99mTc-SS-04 appears to be an excellent candidate for
SPECT imaging of sst2-positive tumours and is a prom-
ising option for further modification of the peptide
motif. The pharmacokinetics of 99mTc-SS-04 demon-
strate once again that the 99mTcO2(N4) core offers
favourable pharmacokinetic features for small peptides
and may potentially be the 99mTc-labelling strategy of
choice.
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